bluebird bio (NASDAQ:BLUE) Downgraded to “Underweight” Rating by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered shares of bluebird bio (NASDAQ:BLUE) from a neutral rating to an underweight rating in a research note published on Friday morning, MarketBeat Ratings reports.

Other research analysts have also recently issued research reports about the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of bluebird bio in a research note on Thursday, August 15th. Robert W. Baird lowered their price target on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Thursday, August 15th. Wells Fargo & Company dropped their price target on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Wednesday, September 25th. Barclays reduced their price objective on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a research note on Thursday, August 15th. Finally, StockNews.com began coverage on shares of bluebird bio in a report on Sunday, November 10th. They issued a “sell” rating for the company. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $3.03.

bluebird bio Stock Up 3.8 %

NASDAQ:BLUE opened at $0.33 on Friday. bluebird bio has a 1-year low of $0.32 and a 1-year high of $5.53. The company has a market capitalization of $64.57 million, a PE ratio of -0.18 and a beta of 0.76. The firm’s 50-day moving average price is $0.49 and its 200-day moving average price is $0.78. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.68 and a quick ratio of 0.57.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. bluebird bio had a negative return on equity of 238.15% and a negative net margin of 565.74%. The business had revenue of $18.57 million during the quarter. On average, equities analysts predict that bluebird bio will post -1.41 EPS for the current fiscal year.

Hedge Funds Weigh In On bluebird bio

A number of institutional investors and hedge funds have recently made changes to their positions in BLUE. Mirae Asset Global Investments Co. Ltd. increased its holdings in bluebird bio by 38.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock valued at $416,000 after buying an additional 90,139 shares during the last quarter. SG Americas Securities LLC grew its position in shares of bluebird bio by 458.8% during the 1st quarter. SG Americas Securities LLC now owns 80,032 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 65,710 shares during the period. Vanguard Group Inc. increased its stake in shares of bluebird bio by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after purchasing an additional 1,723,081 shares in the last quarter. American International Group Inc. raised its holdings in bluebird bio by 77.4% in the 1st quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 41,177 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in bluebird bio by 113.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 29,113 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.